查詢結果分析
來源資料
相關文獻
- 癌因性疲憊症治療新趨勢
- 中醫藥治療癌因性疲憊症的研究進展
- 治療癌因性疲憊之新藥介紹--黃耆多醣
- 癌因性疲憊的中醫治療病例報告
- 末期腎病患者疲憊之介紹
- 中藥製劑中摻加Aminitrozole, Metronidazole, Ornidazole及Tinidazole之高效液相層析分析
- 八十七年度調製劑中藥檢出西藥情形之分析
- 重振男性雄風輕而易舉--中西藥物面面觀
- 中藥、西藥併服應注意的事項
- Solid-phase Extraction and High Performance Liquid Chromatographic Determination of Steroids Adulterated in Traditional Chinese Medicines
頁籤選單縮合
題名 | 癌因性疲憊症治療新趨勢=New Trends in the Therapy of Cancer-Related Fatigue |
---|---|
作者 | 鄭曉倩; 葉淇臺; 王良順; Cheng, Hsiao-chien; Yeh, Chi-tai; Wang, Liang-shun; |
期刊 | 藥學雜誌 |
出版日期 | 20141200 |
卷期 | 30:4=121 2014.12[民103.12] |
頁次 | 頁13-20 |
分類號 | 414.5 |
語文 | chi |
關鍵詞 | 西藥; 黃耆多醣; 疲憊; 癌因性疲憊症; Astragalus polysaccharides; Fatigue; Cancer-related fatigue; |
中文摘要 | 依據衛生福利部公布國人2012年十大死因中,惡性腫瘤連續30年蟬連台灣十大死 因之首位。醫學科技進步雖然提升病人的存活率,但疾病或治療過程中產生的不適症 狀仍持續困擾患者,對生活品質產生極大影響,超過75%以上接受癌症治療的病人有 疲憊症狀的問題,而此疲憊症狀難以多休息而改善。癌因性疲憊症屬國際疾病分類 (ICD-10) 定義之疾病,其發生機轉可能包括免疫失衡 (immune imbalance)、下視丘- 腦垂體-腎上腺軸 (hypothalamic- pituitary-adrenal axis, HPA axis) 異常活化及貧血,其 中又以免疫失衡問題可能是引起癌因性疲憊症之重要原因;根據美國國家癌症資訊網 癌因性疲憊症指引提出,癌因性疲憊症是可以被治療改善的,其中緩解癌因性疲憊症 的方式包括藥物 (如:止痛劑、抗憂鬱劑、貧血用藥或中草複方) 及非藥物治療 (如: 運動、能量保存、營養及睡眠) 等方式幫助患者改善疲憊。然迄今以治療癌因性疲憊 症為主適應症之藥物,目前全球只有經台灣 TFDA 核准的黃耆多醣注射劑,能增強雙 向免疫調節作用,且改善患者疲憊症狀,進而提升癌症病人生活品質。 |
英文摘要 | The leading cause of death in Taiwan 2012 is malignant tumor, which has remained the top killer during the past three decades. Although the survival rate for cancer has steadily improved due to advancements in diagnostic medical technology, cancer patients still suffer from malaise along with disease progression and treatments; also make great impacts on quality of life. Over 75% of cancer patients with cancer treatment reported fatigue as a universal symptom which was not relieved by rest. Proposed criteria for cancerrelated fatigue (CRF) have been adopted for inclusion in ICD-10-CM. The potential mechanisms underlying CRF include immune imbalance, HPA-axis disruption, and anemia. Alteration of immune homeostasis may be the important mechanism which contributes to CRF. According to National Comprehensive Cancer Network (NCCN) clinical practice guideline, the interventions for CRF include pharmaceutical interventions, such as analgesics, antidepressants, erythropoietin, and botanical medicine, and non-pharmaceutical interventions, such as exercise, energy conservation, nutrition consultation, and sleep therapy. Up to now, Astragalus Polysaccharides (APS) Injection, the TFDA-approved prescription drug, is the only drug labeled with the indication of CRF treatment. APS Injection has the efficacy to alleviate fatigue and improve quality of life among cancer patients via modulating bi-directional immune function. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。